Fumihiko Matsuno
- Immunology and Allergy top 5%
- Cell Adhesion Molecules Research 4
- Cancer Research top 10%
- Oncology top 10%
- Peptidase Inhibition and Analysis 4
- Hematology top 10%
- Multiple Myeloma Research and Treatments 7
-
- Angiogenesis and VEGF in Cancer 6
- Glycosylation and Glycoproteins Research 3
-
- Lymphoma Diagnosis and Treatment 5
-
- Monoclonal and Polyclonal Antibodies Research 4
-
- Amino Acid Enzymes and Metabolism 3
- Co-authors
- Ben K. SeonYuro HarutaMaurice BarcosMasao KondoAkinao HabaNorihiko TakahashiHilda TsaiNaoko Harada
- Partner nations
- JapanUnited StatesSwitzerland
In The Last Decade
Fumihiko Matsuno
31 papers receiving 971 citations
Peers
Comparison fields: 5 of 79
- Immunology and Allergy 102
- Cancer Research 226
- Oncology 345
- Hematology 134
- Molecular Biology 590
Countries citing papers authored by Fumihiko Matsuno
This map shows the geographic impact of Fumihiko Matsuno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiko Matsuno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiko Matsuno more than expected).
Fields of papers citing papers by Fumihiko Matsuno
This network shows the impact of papers produced by Fumihiko Matsuno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiko Matsuno. The network helps show where Fumihiko Matsuno may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fumihiko Matsuno, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2010 | 110 | |
| 3 | 2009 | 1 | |
| 4 | 2009 | 3 | |
| 5 | 2007 | 40 | |
| 6 | 2006 | 16 | |
| 7 | 2003 | 53 | |
| 8 | 2003 | 14 | |
| 9 | 2002 | 69 | |
| 10 | 2000 | 34 | |
| 11 | 1999 | 3 | |
| 12 | 1999 | 16 | |
| 13 | Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | 1997 | 137 |
| 14 | Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. | 1997 | 8 |
| 15 | 1996 | 59 | |
| 16 | Establishment of the novel B acute lymphoblastic leukemia (FAB L3) cell line KHM-10B with a 13q34 abnormality and constitutive expression of c-myc and max during cell cycle. | 1995 | 6 |
| 17 | 1993 | 4 | |
| 18 | 1993 | 6 | |
| 19 | 1993 | 2 | |
| 20 | 1992 | 3 |
About Fumihiko Matsuno
Fumihiko Matsuno is a scholar working on Hematology, Immunology and Allergy and Oncology, having authored 31 papers that have together received 986 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (7 papers), Angiogenesis and VEGF in Cancer (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Peptidase Inhibition and Analysis (4 papers), Cell Adhesion Molecules Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Amino Acid Enzymes and Metabolism (3 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Immunology and Allergy (102 citations), Cancer Research (226 citations) and Oncology (345 citations). Fumihiko Matsuno has collaborated with scholars based in Japan, United States and Switzerland. Frequent co-authors include Ben K. Seon, Yuro Haruta, Maurice Barcos, Masao Kondo, Akinao Haba, Norihiko Takahashi, Hilda Tsai, Naoko Harada, Hiroaki Mitsuya and Hiroyuki Hata. Their work appears in journals such as Cancer Research, FEBS Letters and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.